You are in:Home/Publications/Secretion of glucagon- like peptide-1 (GLP-1) in type 2 diabetic patients: Study of its relation to glucose lowering effect of dipeptidyl peptidase IV (DPP-IV) inhibitors. | |
Dr. Rizk Sayad Rizk Sarhan :: Publications: |
Title: | Secretion of glucagon- like peptide-1 (GLP-1) in type 2 diabetic patients: Study of its relation to glucose
lowering effect of dipeptidyl peptidase IV (DPP-IV) inhibitors. |
Authors: | Rizk Sayad Rizk Sarhan, Atef Ahmed Ebraheem, Mohammed Shawky El-Sayed, Roshdy Khalf Allah, Khaled Mostafa Belal |
Year: | 2015 |
Keywords: | glucagon- like peptide-1, Type2 DM, dipeptidyl peptidase IV (DPP-IV) inhibitors,GLP-1 level, incretin hormone, incretin based therapy |
Journal: | Nature and Science |
Volume: | 13(6) |
Issue: | ISSN: 1545- 0740) |
Pages: | 75-87 |
Publisher: | Rizk Sayad Rizk Sarhan |
Local/International: | International |
Paper Link: | |
Full paper | rizk.sayad_012_28738ns130615_75_87.pdf |
Supplementary materials | Not Available |
Abstract: |
Abstract: Background: (1) Th aims of this study are to investigate the glycemic efficy and predictive parameters of DPP IV inhibitors therapy in Egyptian subjects with type 2 diabetes. (2) Investigate the level and the determinants that affect the secretion of glucagone like peptide-1(GLP-1) in Type2 diabetic patients. Subjects and Methods: This study was conducted on 70 type 2 diabetes patients【35 males & 35 females】 under known antidiabetic drugs, Their ages range was (30-63y) and average mean (46.31±10.75 y), as well as 20 apparently healthy subject's volunteers served as control 【12 males & 8 females】 with age range (28-50y) and SD (37.40±5.04 y). DPP-4 inhibitors were added to every patient after the start of the study. The patients were followed at monthly interval for 3 months after the beginning of DPP-4 inhibitors therapy. Results: GLP-1 levels were significantly decreased in DM subjects compared to controls (261.33± 9.37 vs.75.48 ± 20.81pg/mL, p |